Mode of Action

Mulpleo promotes platelet production from within1

Mulpleo acts on the haematopoietic stem cells and on the transmembrane domain of human thrombopoietin (TPO) receptors expressed in megakaryocytes.1

This stimulates megakaryocyte proliferation and differentiation via a signal transduction pathway similar to endogenous TPO, leading to thrombocytopoiesis and increased platelet count in patients.1

Mulpleo binds to TPO receptors at all stages of thrombocytopoiesis2

<p>Mulpleo binds to TPO receptors at all stages of thrombocytopoiesis<sup>2</sup></p>

Adapted from Kaushansky K, 1998.²

References

1

Mulpleo (lusutrombopag) Summary of Product Characteristics.

2

Kaushansky K. N Engl J Med. 1998;339(11):746–754.

Efficacy

Read about Mulpleo’s proven efficacy across its clinical trials.

Safety

Find out about Mulpleo's safety profile.

You are now leaving the UK website for Mulpleo.

Continue Return to site

PP-UK-LUS-0315. Date of preparation: January 2023.